全文获取类型
收费全文 | 93348篇 |
免费 | 9215篇 |
国内免费 | 4372篇 |
专业分类
耳鼻咽喉 | 903篇 |
儿科学 | 4196篇 |
妇产科学 | 448篇 |
基础医学 | 9993篇 |
口腔科学 | 7605篇 |
临床医学 | 8305篇 |
内科学 | 13327篇 |
皮肤病学 | 662篇 |
神经病学 | 2341篇 |
特种医学 | 3556篇 |
外国民族医学 | 26篇 |
外科学 | 29983篇 |
综合类 | 12323篇 |
现状与发展 | 20篇 |
一般理论 | 2篇 |
预防医学 | 2143篇 |
眼科学 | 1395篇 |
药学 | 3693篇 |
35篇 | |
中国医学 | 1706篇 |
肿瘤学 | 4273篇 |
出版年
2024年 | 113篇 |
2023年 | 1312篇 |
2022年 | 1683篇 |
2021年 | 3281篇 |
2020年 | 3386篇 |
2019年 | 3455篇 |
2018年 | 3410篇 |
2017年 | 3330篇 |
2016年 | 3259篇 |
2015年 | 3374篇 |
2014年 | 5614篇 |
2013年 | 7065篇 |
2012年 | 4708篇 |
2011年 | 5748篇 |
2010年 | 5144篇 |
2009年 | 5067篇 |
2008年 | 5074篇 |
2007年 | 5315篇 |
2006年 | 5168篇 |
2005年 | 4696篇 |
2004年 | 3943篇 |
2003年 | 3359篇 |
2002年 | 2712篇 |
2001年 | 2325篇 |
2000年 | 1950篇 |
1999年 | 1592篇 |
1998年 | 1373篇 |
1997年 | 1266篇 |
1996年 | 1144篇 |
1995年 | 881篇 |
1994年 | 980篇 |
1993年 | 610篇 |
1992年 | 729篇 |
1991年 | 547篇 |
1990年 | 402篇 |
1989年 | 392篇 |
1988年 | 370篇 |
1987年 | 264篇 |
1986年 | 225篇 |
1985年 | 286篇 |
1984年 | 220篇 |
1983年 | 156篇 |
1982年 | 187篇 |
1981年 | 147篇 |
1980年 | 131篇 |
1979年 | 125篇 |
1978年 | 128篇 |
1977年 | 94篇 |
1976年 | 86篇 |
1975年 | 41篇 |
排序方式: 共有10000条查询结果,搜索用时 62 毫秒
91.
目的探讨血小板第4因子(platelet factor 4,PF4)对5.0 Gy γ射线全身照射小鼠的骨髓基质细胞(bone marrow stromal cells,BMSCs)的保护作用,进一步探讨PF4对造血的辐射防护机制.方法30只雄性小鼠随机分为3组:①放射组,②PF4保护组,③对照组.小鼠照射前分别于26和20 h腹腔内注射PF4,每次剂量50 μg/kg.于照射后3 d取骨髓细胞体外培养,分别计数培养后3、7和14 d的骨髓基质细胞集落(CFU-F);在培养后10 d流式细胞仪检测细胞周期.结果3组中,照射组3 d的CFU-F数量与PF4保护组差异无统计学意义,7和14 d的CFU-F数量PF4保护组较照射组明显增加.流式细胞仪检测结果表明3组中照射组G0+G1期细胞明显高于其余两组,S,G2+M期细胞明显低于其余两组.结论PF4对照射小鼠的骨髓基质细胞有保护作用,促进造血重建. 相似文献
92.
V. Schmitz U. P. Neumann G. Puhl Z. V. Tran P. Neuhaus J. M. Langrehr 《American journal of transplantation》2006,6(2):379-385
Choledochojejunostomy (CJS) is commonly used for biliary reconstruction in liver transplantation for primary sclerosing cholangitis (PSC). We alternatively performed choledochoduodenostomy (CDS) and side-to-side choledochodocholedochstomy in a large cohort of patients. Fifty-one patients with PSC, transplanted between 1988 and 2000, were analyzed retrospectively. Biliary reconstruction was CDS in 25 (49%), CJS in 20 (39%) and CC in 6 transplantations (12%). Biliary leaks occurred in the early follow-up (< or =41 days) only in CDS patients (20%). However, in the late follow-up (>4 months), stricturing of anastomosis was found once in CDS (4%) and CJS (5%). Later (>9 months), intrahepatic bile duct strictures were diagnosed in four CDS (16%), one CJS (5%) and one CC (17%) patient(s). In 48% of CDS (12/25), 60% of CJS (12/20) and 17% of CC (1/6) at least one incidence of cholangitis was observed. Overall, biliary complication rates were significantly higher in CDS (40%) than CJS (10%) and CC (17%); of those none in CC and 12% in CDS were anastomosis-related. Graft/patient survival showed no significant differences among groups. Based on our results we consider CJS the standard method for biliary reconstruction in PSC; however, in selected cases where CJS is difficult to accomplish because of previous surgery or for retransplantation, CDS may present an alternative technique. 相似文献
93.
原位肝移植术后缺血型胆道病变20例 总被引:1,自引:1,他引:0
目的探讨原位肝移植术后缺血型胆道病变(ITBL)的病因及预防、诊断和治疗的措施。方法回顾性分析1999年2月至2005年4月间291例次原位肝移植后发生ITBL患者的临床资料。结果291例次原位肝移植术后共发生ITBL 20例(6.9%)。术后发生ITBL的高危因素为:原发病为重型乙型肝炎、供受者ABO血型不符、供肝冷保存时间超过12h和术后肝动脉病变。其发生率分别为12.5%(9/71)、20.0%(2/10)、11.1%(9/81)和60%(3/5)。采用药物、经内镜逆行胰胆管造影(ERCP)介入、胆道外科手术及再次肝移植等方法治疗,有效率为80.0%(16/20)、治愈率为50.0%(10/20),与ITBL相关的病死率为10.0%(2/20),与ITBL相关的移植物功能丧失发生率为20.0%(4/20)。结论针对ITBL的高危因素进行相应处理是预防ITBL的有效措施。胆道造影和核磁共振胆胰管成像对诊断ITBL有很高的敏感性和特异性。根据不同的病因和病变程度采用适当的方法治疗ITBL,可获得良好的疗效。 相似文献
94.
肝移植术后糖尿病危险因素分析 总被引:2,自引:0,他引:2
目的 探讨肝移植术后糖尿病(PTDM)的发生及发展的危险因素。方法 回顾性分析98例肝移植受者的临床资料。根据其肝移植术后是否发生糖尿病,分为糖尿病组(36例)和非糖尿病组(62例)。以术前和术后可能的9个危险因素作为分析指标,进行这些指标的单因素分析和χ^2检验。结果 在对两组患者的年龄、乙型肝炎病毒(HBV)感染情况、有无肝硬化及肝硬化的程度、术前糖耐量情况、免疫抑制剂的选择及其血药浓度、激素的使用时间的比较分析中发现:术前肝硬化患者PTDM的发生率明显高于无肝硬化者;肝硬化失代偿期患者PTDM的发生率高于代偿期。术前糖耐量异常的患者PTDM的发生率明显高于糖耐量正常者。激素半年内撤离的患者PTDM的发生率明显低于半年内未撤离者。而两组患者的年龄、HBV的感染情况、免疫抑制剂的选择及其血药浓度相比较,差异均无统计学差异。结论 肝硬化、尤其是肝硬化失代偿期,糖耐量异常,长期使用激素是PTDM发生的危险因素。 相似文献
95.
上肢骨肿瘤切除后的自体骨移植重建 总被引:1,自引:0,他引:1
目的探讨应用自体骨移植对上肢骨肿瘤切除后的骨缺损修复重建的效果。方法1998年8月~2004年3月,收治上肢骨肿瘤切除后的骨缺损16例。男8例,女8例。年龄7~45岁。经病理确诊,肱骨近端尤文肉瘤和骨肉瘤各1例;肱骨远端尤文肉瘤2例;桡骨远端骨巨细胞瘤8例,高分化软骨肉瘤2例,恶性纤维组织细胞瘤和骨肉瘤各1例。2例肱骨近端肿瘤行自体锁骨代肱骨;2例肱骨远端肿瘤行自体腓骨代肱骨;12例桡骨远端肿瘤中,1例行自体髂骨移植,11例行自体腓骨代桡骨进行重建。采用MSTS系统进行术后功能评价。结果2例肱骨近端自体锁骨移植患者分别随访36个月和12个月,术后保持部分肩关节前屈和后伸功能,但外展功能丧失;MSTS评分分别为23分和22分。2例肱骨远端自体腓骨移植患者分别随访4个月和6个月,肘关节功能良好,移植骨连接处已经出现骨愈合;MSTS功能评分分别为24分和19分。12例桡骨远端自体骨移植患者中11例随访6~75个月,功能良好,无明显并发症;1例髂骨植骨的桡骨远端骨巨细胞瘤术后3个月移植骨完全愈合,至今随访75个月,肿瘤无复发。MSTS功能评分18~27分,平均22.6分。结论自体骨移植在上肢骨肿瘤切除后骨缺损的重建,尤其是儿童的骨缺损重建中,是一种较好的方法。 相似文献
96.
BACKGROUND: Recent guidelines suggest supplementation with ergocalciferol (vitamin D(2)) in chronic kidney disease stages 3 and 4 patients with elevated parathyroid hormone (PTH) levels and 25-hydroxyvitamin D (25OHD) levels <75 nmol/l. These guidelines are also applied to renal transplant patients. However, the prevalence rates of 25OHD deficiency and its association with PTH levels in renal transplant populations have not been extensively examined. We aimed to document the prevalence rates of 25OHD deficiency [defined by serum levels <40 nmol/l (<16 ng/ml)] and insufficiency [<75 nmol/l (<30 ng/ml)] in a single renal transplant centre, and examine its relationship with PTH levels. METHODS: Serum 25OHD and PTH concentrations were measured in 419 transplant patients attending a single renal transplant clinic over a 4-month period. Demographic and biochemical data were also collected, including serum creatinine, calcium, phosphate and albumin. Simple and multiple linear regression analysis were performed. RESULTS: In 27.3% of the patients, 25OHD deficiency was present, and 75.5% had insufficiency. On univariate analysis, 25OHD, serum albumin and estimated glomerular filtration rate (eGFR) were significantly associated with PTH levels (P < 0.0001, P = 0.004 and P < 0.0001, respectively). Multiple linear regression demonstrated that only 25OHD, eGFR and serum phosphate were significantly predictive of PTH levels (R(2) = 0.19, P < 0.0001). In this model, a 75 nmol/l increase in 25OHD will only result in a maximal reduction in PTH of 2.0 pmol/l. CONCLUSIONS: We conclude that 25OHD deficiency and insufficiency are common in renal transplant patients and may exacerbate secondary hyperparathyroidism. However, 25OHD, eGFR and phosphate only account for 19% of the variability in PTH levels. In addition, even a large increase in serum 25OHD levels is likely to result in only a small reduction in PTH. Therefore, alternative approaches to managing hyperparathyroidism in renal transplant recipients rather than supplementation with ergocalciferol are warranted. 相似文献
97.
Dino Donataccio Francine Roggen Chantal De Reyck Catherine Verbaandert Monique Bodeus Jan Lerut 《Transplant international》2006,19(1):38-43
The use of livers from anti-hepatitis B core (HBc) positive donors can alleviate donor shortage. Nineteen of 367 (6%) adults receiving anti-HBc positive allografts [three were hepatitis B antigen (HBsAg) negative, hepatitis B antibody (HBsAb) positive; four were HBsAg positive and 12 were not exposed to hepatitis B viral (HBV) infection] were retrospectively reviewed. In HBsAg negative recipients, immunoprophylaxis (IP) was guided by viral serology and immunohistochemistry (IH) of day 0 and day 7 liver biopsies. If IH was negative, IP was stopped. None of three HBsAg negative, HBsAb positive recipients infected; one (replicating) of four HBsAg positive recipients reinfected and seven of eight (87.5%) HBsAg, HBsAb negative recipients, who did not receive long-term IP, infected after a median time of 2 years (range 1-5); one patient died of liver failure. Four HBsAg, HBsAb negative recipients, receiving life-long IP, remained infection free. Anti-HBc positive donor livers must be directed selectively first to HBsAg positive recipients, next to recipients having HBV antibodies and finally to HBV-naive recipients. Identification of both donor and recipient risk factors for HBV infection before transplantation allows indiscriminate use of antiviral prophylaxis. The necessity for IP therapy should be guided by HBV-DNA testing of donor liver tissue and serum. IH of early liver biopsies is an unreliable marker for predicting antiviral treatment requirements. 相似文献
98.
目的分析体外培养的骨髓单个核细胞持续分泌促血管生长因子的能力。方法从大鼠胫骨及股骨采集骨髓,密度梯度离心法分离出骨髓单个核细胞进行体外培养,并连续收集4周培养上清液。酶联免疫吸附实验(ELISA)法测定培养上清液中碱性成纤维细胞生长因子(bFGF)、血管内皮细胞生长因子(VEGF)和白介素-1β(IL-1β)等因子水平。结果第1、2、3、4周骨髓单个核细胞体外培养上清液中VEGF分别为(24.40±7.99)pg/m、l(89.28±5.13)pg/m、l(115.24±10.08)pg/m、l(157.00±15.64)pg/m l;bFGF含量分别为(52.72±2.13)pg/m、l(48.10±6.41)pg/m、l(44.71±3.21)pg/m、l(25.61±2.42)pg/m l;IL-1β含量分别为:(31.28±5.44)pg/m、l(71.87±3.01)pg/m、l(55.77±11.94)pg/m、l(41.75±9.14)pg/m。l结论体外培养骨髓单个核细胞可持续分泌VEGF、bFGF、IL-1β等多种促血管生长因子。 相似文献
99.
100.
Pancreatic Panniculitis Associated with Allograft Pancreatitis and Rejection in a Simultaneous Pancreas–Kidney Transplant Recipient 总被引:1,自引:0,他引:1
J. L. Pike J. C. Rice R. L. Sanchez E. B. Kelly B. C. Kelly 《American journal of transplantation》2006,6(10):2502-2505
Pancreatic panniculitis is an uncommon condition that can occur in association with pancreatic disease. We present a case of pancreatic panniculitis in a female pancreas-kidney transplant recipient 5 months post-transplant. The patient was on standard immunosuppressive medications and had acute rejection of her renal allograft. The diagnosis of allograft pancreatitis and rejection presenting with pancreatic panniculitis was supported clinically, histopathologically and by laboratory and imaging data. This is the fourth case of pancreatic panniculitis occurring in a transplant recipient and the first in a simultaneous pancreas-kidney transplant recipient. It is also the first case associated with allograft rejection. Clinicians should be aware that pancreatic panniculitis may be a manifestation of underlying allograft pancreatic disease. 相似文献